Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367550 | 0.90 | MAPT (0.57) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2367243 | 0.89 | POLB (0.61) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2368399 | 0.89 | PTGER4 (0.52) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1923270 | 0.87 | PTGDR2 (0.47) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2367686 | 0.86 | POLB (0.59) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2367782 | 0.85 | RAB9A (0.55) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2368030 | 0.84 | MAPT (0.55) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2368159 | 0.83 | MEN1 (0.61) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL15329651 | 0.83 | PTGDR2 (0.44) | POLBMEN1KMT2ARAB9AMAPT | |
| SCHEMBL2368342 | 0.81 | POLB (0.53) | POLBMEN1KMT2APTGER4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | POLB 3739/4885MEN1 4834/4885KMT2A 3195/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | POLB 3817/4885MEN1 3507/4885KMT2A 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.